Stock Ratings / Health Care / PBYI / options

DRUG (46) EVO (47) CBIO (29) ARVN (23) ⌘ Pro Terminal →

Puma Biotechnology Inc (PBYI) Options Positioning, Max Pain & Unusual Sweeps

$10.54 -0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.55

Puma Biotechnology Inc (PBYI) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (75% profit margin, 29% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate) →

ROARABLE B- • BUY Cap $544.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBYI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Puma Biotechnology Inc (NASDAQ: PBYI) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $10.54 (-0.75% 1D, market cap $544.1M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 17/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBYI ranks #81 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBYI compare to DRUG and EVO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBYI carries a Roarable B- (71/100 RQD), trailing P/E of 17.5x, gross margin of 74.5%, and ROIC of 29.3%. By comparison, DRUG (Bright Minds Biosciences Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $556.7M) and EVO (Evotec SE) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $562.1M). Among the 5-stock peer group, PBYI leads on earnings multiple (17.5x) while PBYI leads on capital efficiency (29.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBYI?

▼

Per PBYI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401667), Puma Biotechnology Inc generated $228.4M in revenue (-0.9% YoY), $31.1M in net income, and $41.7M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.55 (+0.10%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 18.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY • 68.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBYI)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (71/100 Composite)

🔍 WHY PBYI SCORES 71/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+17/20 pts (24% of score)

FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 54.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)

Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$10.29-0.8% Next Q

Q2 (-2Q)

Grade B-$10.21+6.3% Next Q

Q3 (-1Q)

Grade B-$10.85-2.9% Next Q

Current

Grade B-$10.54+6.8% Hist 90D α

Trajectory: C+ (63) → B- (71)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBYI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 71/100 (B-) score, PBYI faces multiple-compression risk if 17.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 72.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.84) or 200D SMA ($7.93) invalidates the momentum regime and cuts Target Base ($11.16) toward Bear Floor ($8.64).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBYI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBYI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 71%NO 29%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±9.2%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PBYI)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PBYI.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating PBYI & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on PBYI
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBYI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.97%🛡️ HOLDING TREND SUPPORT

2026-11-02O $10.62H $10.62L $10.54C $10.54VOL 224.3K

RES: $11.76SUP: $10.19SMA50: $9.84SMA200: $7.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBYI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBYI Butterfly Map → + Track PBYI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

10.5%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBYI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBYI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBYI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBYI)

Health Care Rank #81 of 1016 ⚔️ DRUG vs PBYI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBYI vs. DRUG, EVO, CBIO, ARVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Puma Biotechnology Inc (PBYI) ranks #81 by composite RQD confidence (71/100, grade B-) and #432 by equity capitalization ($544.1M). Within this direct 5-issuer industry benchmark cohort, PBYI leads on earnings valuation at 17.5x trailing P/E, while PBYI leads on capital efficiency and profitability with 29.3% ROIC and 74.5% gross margin. PBYI currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBYI ACTIVE Puma Biotechnology Inc	B-	71/100	17.5x	74.5%	29.3%	-0.75%	$544.1M	Benchmark Subject
DRUG Bright Minds Biosciences Inc.	D	46/100	—	—	—	+2.48%	$556.7M	/drug-vs-pbyi →
EVO Evotec SE	D	47/100	—	—	—	-1.56%	$562.1M	/evo-vs-pbyi →
CBIO Crescent Biopharma Inc.	E	29/100	—	—	-35.0%	+4.22%	$522.6M	/cbio-vs-pbyi →
ARVN Arvinas Inc.	E	23/100	—	—	-32.1%	+3.95%	$516.6M	/arvn-vs-pbyi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401667

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Puma Biotechnology Inc (PBYI) reported GAAP revenue of $228.4M (-0.9% vs. FY2024 revenue of $230.5M , and -3.1% cumulative change since FY2023) , GAAP net income of $31.1M, operating cash flow of $41.8M, and free cash flow of $41.7M (+7.4% YoY). On the balance sheet, PBYI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$228.4M	$31.1M	$41.8M	$41.7M	$216.3M	$0
FY2024 (FY)	2024-12-31	$230.5M	$30.3M	$38.9M	$38.9M	$213.3M	$21.7M
FY2023 (FY)	2023-12-31	$235.6M	$21.6M	$27.0M	$27.0M	—	—

3. PBYI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBYI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PBYI compare to DRUG and EVO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PBYI?

Where is PBYI trading relative to its 50-day, 200-day, and 52-week technical levels?

PBYI last traded at $10.54 (-0.75% on volume of 224,300 shares), positioning the stock +7.11% above its 50-day simple moving average ($9.84) and +32.91% above its 200-day simple moving average ($7.93). Across its 52-week range of $4.58 to $11.50, PBYI sits at the 86.1% percentile with a 14-day RSI of 54.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($9.57 to $11.51).